Herpesvirus infections in organ transplant recipients

Clinical and Diagnostic Laboratory Immunology

Volumn 10, Issue 1, 2003, Pages 1-7

  Jenkins, Frank J ^a   Rowe, David T ^a   Rinaldo Jr , Charles R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; VALACICLOVIR; VALGANCICLOVIR; VARICELLA ZOSTER VACCINE;

ANEMIA; CLINICAL FEATURE; DEVELOPED COUNTRY; DOWN REGULATION; DRUG BIOAVAILABILITY; EPSTEIN BARR VIRUS; GENETIC CODE; HERPES SIMPLEX VIRUS 1; HERPES VIRUS; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; IMMUNOCOMPETENCE; INFECTION RISK; NAUSEA; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT INFECTION; RISK ASSESSMENT; SEIZURE; SHORT SURVEY; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSMISSION; VOMITING;

HERPESVIRIDAE INFECTIONS; HUMANS; IMMUNOSUPPRESSION; INFECTION CONTROL; ORGAN TRANSPLANTATION; SEROLOGIC TESTS; TRANSPLANTATION IMMUNOLOGY;

EID: 0037252785     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.10.1.1-7.2003     Document Type: Short Survey

References (122)

1. Aebischer, M. C., L. B. Zala, and L. R. Braathen. 1997. Kaposi's sarcoma as manifestation of immunosuppression in organ transplant recipients. Dermatology 195:91-92.
2. Agut, H., H. Collandre, J. T. Aubin, D. Guetard, V. Favier, D. Ingrand, L. Montagnier, and J. M. Huraux. 1989. In vitro sensitivity of human herpesvirus-6 to antiviral drugs. Res. Virol. 140:219-228.
3. Aris, R. M., D. M. Maia, I. P. Neuringer, K. Gott, S. Kiley, K. Gertis, and J. Handy. 1996. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient. Am. J. Respir. Crit. Care Med. 154:1712.
4. Arvin, A. M. 2000. Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol. Blood Marrow Transplant. 6:219-230.
5. Asadullah, K. S., S. Prosch, H. Audring, L Burrnerova, H. D. Volk, W. Sterry, and W. D. Docke. 1999. A high prevalence of cytomegalovirus antigenaemia in patients with moderate to severe chronic plaque psoriasis: an association with systemic tumour necrosis factor a overexpression. Br. J. Dermatol. 141:94-102.
6. Boyle, G. J., M. G. Michaels, and S. A. Webber. 1997. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J. Pediatr. 131:309-313.
7. Brennan, D. C. 2001. Cytomegalovirus in renal transplantation. J. Am. Soc. Nephrol. 12:848-855.
8. Brennan, D. C., and G. G. Singer. 1999. Infectious complications in renal transplantation, p. 1-24. In H. H. Malluche, B. P. Sawaya, R. M. Hakim, M. H. Sayegh, and N. Ismail (ed.), Clinical nephrology dialysis and transplantation. Bosch-Druck, Landshut, Germany.
9. Cacciarelli, T. V., M. Green, R. Jaffe, G. V. Mazariegos, A. Jain, J. J. Fung, and J. Reyes. 1998. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy, Transplantation 66:1047-1052.
10. Chakrabarti, S., D. Pillay, D. Ratcliffe, P. A. Cane, K. E. Collingham, and D. W. Milligan. 2000. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. J. Infect. Dis. 181:2055-2058.
11. Chang, Y., E. Cesarman, M. S. Pessin, F. Lee, J. Culpepper, D. M. Knowles, and P. S. Moore. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869.
12. Chang, Y., and P. S. Moore. 1996. Kaposi's sarcoma (KS)-associated herpesvirus and its role in KS. Infect. Agents Dis. 5:215-222.
13. Chen, Y., C. Scieux, V. Garrait, G. Socie, V. Rocha, J. M. Molina, D. Thouvenot, F. Morfin, L. Hocqueloux, L. Garderet, H. Esperou, F. Selimi, A. Devergie, G. Leleu, M. Aymard, F. Morinet, E. Gluckman, and P. Ribaud. 2000. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin. Infect. Dis. 31:927-935.
14. Colleoni, G. W., J. S. Oliveira, D. M. Borducchi, M. A. Fernandes, S. T. Da Silva, A. C. Alves, M. F. De Franco, J. Kerbauy, and J. O. Pestana. 2000. Post-transplant lymphoproliferative disorders (PTLD) after renal transplantation: management and evolution of seven cases among 1002 renal transplants in Sao Paulo, Brazil. Leuk. Lymphoma 39:145-150.
15. Cone, R. W., M. L. Huang, L. Corey, J. Zeh, R. Ashley, and R. Bowden. 1999. Human herpesvirus 6 infections after bone marrow transplantation: clinical and virologic manifestations. J. Infect. Dis. 179:311-318.
16. Corchero, J. L., E.-C. Mar, T. J. Spira, P. E. Pellett, and N. Inoue. 2001. Comparison of serologic assays for detection of antibodies against human herpesvirus 8. Clin. Diagn. Lab. Immunol. 8:913-921.
17. Deeg, H. J., J. Sanders, P. Martin, A. Fefer, P. Neiman, J. Singer, R. Storb, and E. D. Thomas. 1984. Secondary malignancies after marrow transplantation. Exp. Hematol. 12:660-666.
18. Desjardin, J. A., L. Gibbons, E. Cho, S. E. Supran, M. E. Falagas, B. G. Werner, and D. R. Snydman. 1998. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. J. Infect. Dis. 178:1783-1786.
19. Docke, W. D., S. Prosch, E. Fietze, V. Kimel, H. Zuckermann, C. Klug, U. Syrbe, D. H. Kruger, R. Von Baehr, and H.-D. Volk. 1994. Cytomegalovirus reactivation and tumour necrosis factor. Lancet 343:268-269.
20. Dockrell, D. H., J. Prada, M. F. Jones, R. Patel, A. D. Badley, W. S. Harmsen, D. M. Ilstrup, R. H. Wiesner, R. A. Krom, T. F. Smith, and C. V. Paya. 1997. Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J. Infect. Dis. 176:1135-1140.
21. Donati, M., M. Zuckerman, A. Dhawan, N. Hadzic, N. Heaton, P. North-Lewis, and G. Mieli-Vergani. 2000. Response to varicella immunization in pediatric liver transplant recipients. Transplantation 70:1401-1404.
22. Durandy, A. 2001. Anti-B cell and anti-cytokine therapy for the treatment of post-transplant lymphoproliferative disorder: past, present, and future. Transplant. Infect. Dis. 3:104-107.
23. Ellis, D., R. Jaffe, M. Green, J. J. Janosky, S. Lombardozzi-Lane, R. Shapiro, V. Scantlebury, C. Vivas, and M. L. Jordan. 1999. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Transplantation 68:997-1003.
24. Faye, A., P. Quartier, Y. Reguerre, P. Lutz, A. S. Carret, A. Dehee, P. Rohrlich, M. Peuchmaur, A. Matthieu-Boue, A. Fischer, and E. Vilmer. 2001. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br. J. Haematol. 115:112-118.
25. Feldhoff, C. M., H. H. Balfour, Jr., R. L. Simmons, J. S. Najarian, and S. M. Mauer. 1981. Varicella in children with renal transplants. J. Pediatr. 98:25-31.
26. Fietze, E., S. Prosch, P. Reinke, J. Stein, W. D. Docke, G. Staffa, S. Loning, S. Devaux, F. Emmrich, R. Von Baehr, D. H. Kruger, and D. H. Volk. 1994. Cytomegalovirus infection in transplant recipients. Transplantation 58:675-680.
27. Fischer, A., S. Blanche, J. Le Bidois, P. Bordigoni, J. L. Garnier, P. Niaudet, F. Morinet, F. Le Deist, A. M. Fischer, C. Griscelli, et al. 1991. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N. Engl. J. Med. 324:1451-1456.
28. Frances, C., C. Mouquet, A. G. Marcelin, S. Barete, R. Agher, D. Charron, H. Benalia, N. Dupin, J. C. Piette, M. O. Bitker, and V. Calvez. 2000. Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. Transplantation 69:1776-1779.
29. Frenkel, N., E. C. Schirmer, L. S. Wyatt, G. Katsafanas, E. Roffman, R. M. Danovich, and C. H. June. 1990. Isolation of a new herpesvirus from human CD4+ T cells. Proc. Natl. Acad. Sci. USA 87:748-752.
30. Gluckman, E., J. Lotsberg, A. Devergie, X. M. Zhao, R. Melo, M. Gomez-Morales, T. Nebout, M. C. Mazeron, and Y. Perol. 1983. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet ii:706-708.
31. Green, M., J. Reyes, and D. Rowe. 1998. New strategies in the prevention and management of Epstein-Barr virus infection and posttransplant lymphoproliferative disease following solid organ transplantation. Curr. Opin. Organ Transplant. 3:143-147.
32. Green, M., J. Reyes, S. Webber, and D. Rowe. 2001. The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transplant Infect. Dis. 3:97-103.
33. Griffiths, P. D., M. Ait-Khaled, C. P. Bearcroft, D. A. Clark, A. Quaglia, S. E. Davies, A. K. Burroughs, K. Rolles, I. M. Kidd, S. N. Knight, S. M. Noibi, A. V. Cope, A. N. Phillips, and V. C. Emery. 1999. Human herpesviruses 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus. J. Med. Virol. 59:496-501.
34. Hanel, M., F. Fiedler, and C. Thorns. 2001. Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Onkologie 24:491-494.
35. Hanto, D. W., G. Frizzera, K. J. Gajl-Peczalska, H. H. Balfour, Jr., and R. L. Simmons. 1985. Acyclovir therapy of Epstein-Barr virus-induced posttransplant lymphoproliferative diseases. Transplant. Proc. 17:89-92.
36. Hanto, D. W., G. Frizzera, K. J. Gajl-Peczalska, K. Sakamoto, D. T. Purtilo, H. H. Balfour, Jr., R. L. Simmons, and J. S. Najarian. 1982. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N. Engl. J. Med. 15:913-918.
37. Haque, T., C. Taylor, G. M. Wilkie, P. Murad, P. L. Amlot, S. Beath, P. J. McKiernan, and D. H. Crawford. 2001. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 72:1399-1402.
38. Harnett, G. B., T. J. Farr, G. R. Pietroboni, and M. R. Bucens. 1990. Frequent shedding of human herpesvirus 6 in saliva. J. Med. Virol. 30:128-130.
39. Harper, M. B. 1995. Pediatric infectious disease emergencies. Curr. Opin. Pediatr. 7:302-308.
40. Hidaka, Y., Y. Liu, M. Yamamoto, R. Mori, C. Miyazaki, K. Kusuhara, K. Okada, and K. Ueda. 1993. Frequent isolation of human herpesvirus 7 from saliva samples. J. Med. Virol. 40:343-346.
41. Humar, A., G. Malkan, G. Moussa, P. Greig, G. Levy, and T. Mazzulli. 2000. Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients. J. Infect. Dis. 181:1450-1453.
42. Ippoliti, G., L. Martinelli, F. Lorenzutti, S. Incardona, M. Negri, P. Balduzzi, B. Rovati, E. Aseari, and M. Vigano. 1994. Posttransplant lymphoproliferative disease after heart transplantation on Sandimmune therapy: treatment with interferon alfa-2b and intravenous immunoglobulin. Transplant. Proc. 26:2660-2661.
43. Jenkins, F. J., L. J. Hoffman, and A. Liegey-Dougall. 2002. Reactivation of and primary infection with human herpesvirus 8 among solid-organ transplant recipients. J. Infect. Dis. 185:1238-1243.
44. Kadakia, M. P. 1998. Human herpesvirus 6 infection and associated pathogenesis following bone marrow transplantation. Leuk. Lymphoma 31:251-266.
45. Katsafanas, G. C., E. C. Schirmer, L. S. Wyatt, and N. Frenkel. 1996. In vitro activation of human herpesviruses 6 and 7 from latency. Proc. Natl. Acad. Sci. USA 93:9788-9792.
46. Keay, S., D. Oldach, A. Wiland, D. Klassen, E. Schweitzer, L. V. Abruzzo, D. Kumar, and S. Bartlett. 1998. Posttransplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients. Clin. Infect. Dis. 26:596-600.
47. Khanna, R., S. Bell, M. Sherritt, A. Galbraith, S. R. Burrows, L. Rafter, B. Clarke, R. Slaughter, M. C. Falk, J. Douglass, T. Williams, S. L. Elliott, and D. J. Moss. 1999. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl. Acad. Sci. USA 96:10391-10396.
48. Khanna, R., J. Tellam, J. Duraiswamy, and L. Cooper. 2001. Immunotherapeutic strategies for EBV-associated malignancies. Trends Mol. Med. 7:270-276.
49. Kidd, I. M., D. A. Clark, M. Ait-Khaled, P. D. Griffiths, and V. C. Emery. 1996. Measurement of human herpesvirus 7 load in peripheral blood and saliva of healthy subjects by quantitative polymerase chain reaction. J. Infect. Dis. 174:396-401.
50. Knowles, D. M., E. Cesarman, A. Chadburn, G. Frizzera, J. Chen, E. A. Rose, and R. E. Michler. 1995. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85:552-565.
51. Kogan, D. L., M. Burroughs, S. Emre, T. Fishbein, A. Moscona, C. Ramson, and B. L. Shneider. 1999. Prospective longitudinal analysis of quantitative Epstein-Barr virus polymerase chain reaction in pediatric liver transplant recipients. Transplantation 67:1068-1070.
52. Kusne, S., R. Shapiro, and J. Fung. 1999. Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transplant Infect. Dis. 1:187-203.
53. Kutza, A. S., E. Muhl, H. Hackstein, H. Kirchner, and G. Bein. 1998. High incidence of active cytomegalovirus infection among septic patients. Clin. Infect. Dis. 26:1076-1082.
54. Langston, A. A., I. Redei, A. M. Caliendo, J. Somani, D. Hutcherson, S. Lonial, S. Bucur, J. Cherry, A. Allen, and E. K. Waller. 2002. Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. Blood 99:1085-1088.
55. Lazarovits, A. I., L. A. Tibbles, D. R. Grant, C. N. Ghent, W. J. Wall, M. J. White, and J. H. Joncas. 1994. Anti-B cell antibodies for the treatment of monoclonal Epstein-Barr virus-induced lymphoproliferative syndrome after multivisceral transplantation. Clin. Investig. Med. 17:621-625.
56. Levy, J. A., F. Ferro, D. Greenspan, and E. T. Lennette. 1990. Frequent isolation of HHV-6 from saliva and high seroprevalence of the virus in the population. Lancet 335:1047-1050.
57. Limaye, A. P., M.-L. Huang, E. E. Atienza, J. M. Ferrenberg, and L. Corey. 1999. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. J. Clin. Microbiol. 37:1113-1116.
58. Linde, A. 2001. The importance of specific virus diagnosis and monitoring for antiviral treatment. Antivir. Res. 51:81-94.
59. Ljungman, P. 2001. Prophylaxis against herpesvirus infections in transplant recipients. Drugs 61:187-196.
60. Lowance, D., H. H. Neumayer, C. M. Legendre, J. P. Squifflet, J. Kovarik, P. J. Brennan, D. Norman, R. Mendez, M. R. Keating, G. L. Coggon, A. Crisp, I. C. Lee, et al. 1999. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N. Engl. J. Med. 340:1462-1470.
61. Luppi, M., P. Barozzi, G. Santagostino, R. Trovato, T. F. Schulz, R. Marasca, D. Bottalico, L. Bignardi, and G. Torelli. 2000. Molecular evidence of organ-related transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients. Blood 96:3279-3281.
62. Luppi, M., P. Barozzi, T. F. Schulz, R. Trovato, A. Donelli, F. Narni, J. Sheldon, R. Marasca, and G. Torelli. 2000. Nonmalignant disease associated with human herpesvirus 8 reactivation in patients who have undergone autologous peripheral blood stem cell transplantation. Blood 96:2355-2357.
63. Margolius, L. P. 1995. Kaposi's sarcoma in renal transplant recipients. J. Nephrol. 8:300-304.
64. McDiarmid, S. V., S. Jordan, G. S. Kim, M. Toyoda, J. A. Goss, J. H. Vargas, M. G. Martin, R. Bahar, A. L. Maxfield, M. E. Ament, R. W. Busuttil, and G. S. Lee. 1998. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 66:1604-1611.
65. McGregor, R. S., B. J. Zitelli, A. H. Urbach, J. J. Malatack, and J. C. Gartner, Jr. 1989. Varicella in pediatric orthotopic liver transplant recipients. Pediatrics 83:256-261.
66. McLaughlin, P., A. J. Grillo-Lopez, B. K. Link, R. Levy, M. S. Czuczman, M. E. Williams, M. R. Heyman, I. Bence-Bruckler, C. A. White, F. Cabanillas, V. Jain, A. D. Ho, J. Lister, K. Wey, D. Shen, and B. K. Dallaire. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16:2825-2833.
67. Mendez, J. C., D. H. Dockrell, M. J. Espy, T. F. Smith, J. A. Wilson, W. S. Harmsen, D. Ilstrup, and C. V. Paya. 2001. Human beta-herpesvirus interactions in solid organ transplant recipients. J. Infect. Dis. 183:179-184.
68. Meyers, J. D., N. Flournoy, and E. D. Thomas. 1980. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J. Infect. Dis. 142:338-346.
69. Meyers, J. D., J. C. Wade, C. D. Mitchell, R. Saral, P. S. Lietman, D. T. Durack, M. J. Levin, A. C. Segreti, and H. H. Balfour, Jr. 1982. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am. J. Med. 73:229-235.
70. Mocarski, E. S., and C. T. Courcelle. 2001. Cytomegaloviruses and their replication, p. 2629-2674. In D. M. Knipe et al. (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
71. Montagnino, G., P. L. Bencini, A. Tarantino, R. Caputo, and C. Ponticelli. 1994. Clinical features and course of Kaposi's sarcoma in kidney transplant patients: report of 13 cases. Am. J. Nephrol. 14:121-126.
72. Moosa, M. R., F. K. Treurnicht, E. J. van Rensburg, J. W. Schneider, H. F. Jordaan, and S. Engelbrecht. 1998. Detection and subtyping of human herpesvirus-8 in renal transplant patients before and after remission of Kaposi's sarcoma. Transplantation 66:214-218.
73. Naesens, L., and E. De Clercq. 2001. Recent developments in herpesvirus therapy. Herpes 8:12-16.
74. Nagy, S., R. Gyulai, L. Kemeny, P. Szenohradszky, and A. Dobozy. 2000. Iatrogenic Kaposi's sarcoma: HHV8 positivity persists but the tumors regress almost completely without immunosuppressive therapy. Transplantation 69:2230-2231.
75. Nalesnik, M. A., R. Jaffe, T. E. Starzl, A. J. Demetris, K. Porter, J. A. Burnham, L. Makowka, M. Ho, and J. Locker. 1988. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am. J. Pathol. 133:173-192.
76. Newell, K. A., E. M. Alonso, P. F. Whitington, D. S. Bruce, J. M. Millis, J. B. Piper, E. S. Woodle, S. M. Kelly, H. Koeppen, J. Hart, C. M. Rubin, and J. R. Thistlethwaite, Jr. 1996. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 62:370-375.
77. Olson, A. D., T. C. Shope, and J. T. Flynn. 2001. Pretransplant varicella vaccination is cost-effective in pediatric renal transplantation. Pediatr. Transplant. 5:44-50.
78. Osman, H. K., J. S. Peiris, C. E. Taylor, J. P. Karlberg, and C. R. Madeley. 1997. Correlation between the detection of viral DNA by the polymerase chain reaction in peripheral blood leukocytes and serological responses to human herpesvirus 6, human herpesvirus 7, and cytomegalovirus in renal allograft recipients. J. Med. Virol. 53:288-294.
79. Osman, H. K., J. S. Peiris, C. E. Taylor, P. Warwicker, R. F. Jarrett, and C. R. Madeley. 1996. "Cytomegalovirus disease" in renal allograft recipients: is human herpesvirus 7 a co-factor for disease progression? J. Med. Virol. 48:295-301.
80. Papadopoulos, E. B., M. Ladanyi, D. Emanuel, S. Mackinnon, F. Boulad, M. H. Carabasi, H. Castro-Malaspina, B. H. Childs, A. P. Gillio, and T. N. Small. 1994. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330:1185-1191.
81. Pass, R. F. 2001. Cytomegalovirus, p. 2675-2706. In D. M. Knipe et al. (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
82. Pettersson, E., T. Hovi, J. Ahonen, A. P. Fiddian, K. Salmela, K. Hockerstedt, B. Eklund, E. von Willebrand, and P. Hayry. 1985. Prophylactic oral acyclovir after renal transplantation. Transplantation 39:279-281.
83. Piiparinen, H., K. Höckerstedt, M. Lappalainen, J. Suni, and I. Lautenschlager. 2002. Monitoring of viral load by quantitative plasma PCR during active cytomegalovirus infection of individual liver transplant patients. J. Clin. Microbiol. 40:2945-2952.
84. Prosch, S., C. E. C. Wendt, P. Reinke, C. Priemer, M. Oppert, D. H. Kruger, H.-D. Volk, and W. D. Docke. 2000. A novel link between stress and human cytomegalovirus (HCMV) infection: sympathetic hyperactivity stimulates HCMV activation. Virology 272:357-365.
85. Ratnamohan, V. M., J. Chapman, H. Howse, K. Bovington, P. Robertson, K. Byth, R. Allen, and A. L. Cunningham. 1998. Cytomegalovirus and human herpesvirus 6 both cause viral disease after renal transplantation. Transplantation 66:877-882.
86. Reinke, P., S. Prosch, F. Kern, and H.-D. Volk. 1999. Mechanism of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transplant Infect. Dis. 1:157-164.
87. Remeijer, L., J. Maertzdorf, P. Doornenbal, G. M. Verjans, and A. D. Osterhaus. 2001. Herpes simplex virus 1 transmission through corneal transplantation. Lancet 357:442.
88. Reusser, P. 2002. Challenges and options in the management of viral infections after stem cell transplantation. Support Care Cancer 10:197-203.
89. Reyes, J., M. Green, J. Bueno, N. Jabbour, M. Nalesnik, E. Yunis, S. Kocoshis, M. Kauffman, S. Todo, and T. E. Starzl. 1996. Epstein Barr virus associated posttransplant lymphoproliferative disease after intestinal transplantation. Transplant. Proc. 28:2768-2769.
90. Riddell, S. R., and P. D. Greenberg. 2000. T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. J. Antimicrob. Chemother. 45(Suppl. T3):35-43.
91. Ritter, T., C. Brandt, S. Prosch, A. Vergopoulos, K. Vogt, J. Kolls, and H.-D. Volk. 2000. Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells. Cytokine 12:1163-1170.
92. Rooney, C. M., C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop. 1995. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9-13.
93. Rowe, D. T., L. Qu, J. Reyes, N. Jabbour, E. Yunis, P. Putnam, S. Todo, and M. Green. 1997. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J. Clin. Microbiol. 35:1612-1615.
94. Rowe, D. T., S. Webber, E. M. Schauer, J. Reyes, and M. Green. 2001. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transplant Infect. Dis. 3:79-87.
95. Rubin, R. H. 1994. Infection in the organ transplant recipient, p. 629-705. In R. H. Rubin and L. S. Young (ed.), Clinical approach to infection in the immunocompromised host. Plenum, New York, N.Y.
96. Salahuddin, S. Z., D. V. Ablashi, P. D. Markham, S. F. Josephs, S. Sturzenegger, M. Kaplan, G. Halligan, P. Biberfeld, F. Wong-Staal, and B. Kramarsky. 1986. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 234:596-601.
97. Saral, R., W. H. Burns, O. L. Laskin, G. W. Santos, and P. S. Lietman. 1981. Acyclovir prophylaxis of herpes-simplex-virus infections. N. Engl. J. Med. 305:63-67.
98. Savoldo, B., J. Goss, Z. Liu, M. H. Huls, S. Doster, A. P. Gee, M. K. Brenner, H. E. Heslop, and C. M. Rooney. 2001. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation 72:1078-1086.
99. Schulz, T. F. 1999. Epidemiology of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. Adv. Cancer Res. 76:121-160.
100. Seale, L., C. J. Jones, S. Kathpalia, G. G. Jackson, M. Mozes, M. S. Maddux, and D. Packham. 1985. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. JAMA 254:3435-3438.
101. Shapiro, R. S., A. Chauvenet, W. McGuire, A. Pearson, A. W. Craft, P. McGlave, and A. Filipovich. 1988. Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin. N. Engl. J. Med. 318:1334.
102. Sia, I. G., and R. Patel. 2000. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin. Microbiol. Rev. 13:83-121.
103. Singh, N., and D. R. Carrigan. 1996. Human herpesvirus-6 in transplantation: an emerging pathogen. Ann. Intern. Med. 124:1065-1071.
104. Singh, N., D. R. Carrigan, T. Gayowski, and I. R. Marino. 1997. Human herpesvirus-6 infection in liver transplant recipients: documentation of pathogenicity. Transplantation 64:674-678.
105. Spira, T. J., L. Lam, S. C. Dollard, Y.-X. Meng, C. P. Pau, J. B. Black, D. Burns, B. Cooper, M. Hamid, J. Huong, K. Kite-Powell, and P. E. Pellett. 2000. Comparison of serologic assays and PCR for diagnosis of human herpesvirus 8 infection. J. Clin. Microbiol. 38:2174-2180.
106. Staak, K., S. Prosch, and J. Stein. 1997. Pentoxifylline promotes replication of human cytomegalovirus in vivo and in vitro. Blood 89:3682-3690.
107. Starzi, T. E., M. A. Nalesnik, K. A. Porter, M. Ho, S. Iwatsuki, B. P. Griffith, J. T. Rosenthal, T. R. Hakala, B. W. Shaw, Jr., and R. L. Hardesty. 1984. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet i:583-587.
108. St. George, K., D. T. Rowe, and C. R. Rinaldo, Jr. 2000. Cytomegalovirus, varicella-zoster virus, and Epstein-Barr virus, p. 410-449. In S. Specter, R. L. Hodinka, and S. A. Young (ed.), Clinical virology manual, 3rd ed. American Society for Microbiology, Washington, D.C.
109. Taguchi, Y., D. T. Purtilo, and M. Okano. 1994. The effect of intravenous immunoglobulin and interferon-alpha on Epstein-Barr virus-induced lymphoproliferative disorder in a liver transplant recipient. Transplantation 57:1813-1815.
110. Tanaka, K., T. Kondo, S. Torigoe, S. Okada, T. Mukai, and K. Yamanishi. 1994. Human herpesvirus 7: another causal agent for roseola (exanthem subitum). J. Pediatr. 125:1-5.
111. Tsai, D. E., C. L. Hardy, J. E. Tomaszewski, R. M. Kotloff, K. M. Oltoff, B. G. Somer, S. J. Schuster, D. L. Porter, K. T. Montone, and E. A. Stadtmauer. 2001. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71:1076-1088.
112. van Zanten, J., L. de Leij, J. Prop, M. C. Harmsen, and T. H. The. 1998. Human cytomegalovirus: a viral complication in transplantation. Clin. Transplant. 12:145-158.
113. Venard, V., J. N. Dauendorffer, A. S. Carret, D. Corsaro, D. Edert, P. Bordigoni, and A. Le Faou. 2001. Infection due to acyclovir resistant herpes simplex virus in patients undergoing allogeneic hematopoietic stem cell transplantation. Pathol. Biol. (Paris) 49:553-558.
114. Verschuuren, E. A., S. J. Stevens, G. W. van Imhoff, J. M. Middeldorp, C. de Boer, G. Koeter, T. H. The, and W. van Der Bij. 2002. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 73:100-104.
115. Wang, Q. J., F. J. Jenkins, L. P. Jacobson, L. A. Kingsley, R. D. Day, Z. W. Zhang, Y. X. Meng, P. E. Pellett, K. G. Kousoulas, A. Baghian, and C. R. Rinaldo, Jr. 2001. Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins. Blood 97:2366-2373.
116. Weiss, R. A., D. Whitby, S. Talbot, P. Kellam, and C. Boshoff. 1998. Human herpesvirus type 8 and Kaposi's sarcoma. J. Natl. Cancer Inst. Monogr. 23:51-54.
117. Wyatt, L. S., W. J. Rodriguez, N. Balachandran, and N. Frenkel. 1991. Human herpesvirus 7: antigenic properties and prevalence in children and adults. J. Virol. 65:6260-6265.
118. Yamanishi, K. 2001. Human herpesvirus 6 and human herpesvirus 7, p. 2785-2802. In D. M. Knipe et al. (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
119. Yamanishi, K., T. Okuno, K. Shiraki, M. Takahashi, T. Kondo, Y. Asano, and T. Kurata. 1988. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet i:1065-1067.
120. Yang, J., Q. Tao, I. W. Flinn, P. G. Murray, L. E. Post, H. Ma, S. Piantadosi, M. A. Caligiuri, and R. F. Ambinder. 2000. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 96:4055-4063.
121. Zhu, L., R. Wang, A. Sweat, E. Goldstein, R. Horvat, and B. Chandran. 1999. Comparison of human sera reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and lytic (ORFs 65, K8.1A, and K8.1B) replicative cycles and in immunofluorescence assays with HHV-8-infected BCBL-1 cells. Virology 256:381-392.
122. Zilz, N. D., L. J. Olson, and C. G. McGregor. 2001. Treatment of posttransplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. J. Heart Lung Transplant. 20:770-772.